当前位置: 首页 > 期刊 > 《中国美容医学》 > 2018年第4期
编号:13241985
口服普萘洛尔治疗婴幼儿体表血管瘤的临床研究(4)
http://www.100md.com 2018年2月15日 《中国美容医学》 2018年第4期
     [15]林晓斌,蔡湘娜,纪影畅,等.口服普萘洛尔治疗婴幼儿血管瘤的临床观察[J].汕头大学医学院学报,2013,26(1):33-34.

    [16]郑家伟,张凌,陈正岗.普萘洛尔治疗婴幼儿血管瘤专家共识[J].中国口腔颌面外科杂志, 2013,11(2):161-164.

    [17]徐蒙.普萘洛尔对婴幼儿血管瘤组织中血管内皮生长因子表达的影响[J].中华全科医学, 2013,11(2):222-223.

    [18]史川,王培燊,陈江谊,等.普萘洛尔治疗婴幼儿血管瘤的临床分析[J].廣东医学,2012, 33(9):1327-1328.

    [19]Léautélabrèze C,Sansmartin V.Infantile hemangioma[J].Presse Médicale,2010, 39(4):499-510.

    [20]Bangiyev JN,Gurgel R,Vanderhooft SL,et al.Reversible profound sensorineural hearing loss due to propranolol sensitive hemangioma in an infant with PHACE syndrome [J].Int J Pediatr Otorhinolaryngol,2017,103:55-57.

    [21]Alsmman AH,Mounir A.Combined oral propranolol with intralesional injection of triamcinolone acetonide in treatment of infantile periocular hemangiomas [J]. Clin Ophthalmol,2017,11:2177-2181.

    [22]Rotter A,de Oliveira ZNP.Infantile hemangioma: pathogenesis and mechanisms of action of propranolol [J].J Dtsch Dermatol Ges,2017,15(12):1185-1190.

    [23]Guo X,Zhu X,Liu D,et al.Continuous delivery of propranolol from liposomes-in-microspheres significantly inhibits infantile hemangioma growth[J].Int J Nano Med,2017,12:6923-6936., 百拇医药(彭慧子 周林 杨壮群)
上一页1 2 3 4